|
|
|
|
|
Issue:
115
Page: 8-16
Lemon Balm
Melissa officinalis
Family: Lamiaceae
by Gayle Engels, Josef Brinckmann
HerbalGram.
2017; American Botanical Council
INTRODUCTION
Melissa officinalis, commonly called lemon balm,1 is an erect,
herbaceous perennial that grows to about three feet (1 m) in height. The
species has sparsely pubescent, toothed leaves,2 which have a
fragrance and flavor reminiscent of lemon (Citrus × limon,
Rutaceae). Unlike many members of the mint family, lemon balm does not have
invasive roots. The small, yellow to pinkish-white flowers produce four tiny
seeds, which germinate easily and are primarily responsible for the plant’s
vigorous dispersion.
The genus Melissa is small and
includes only four accepted species (M. officinalis, M. axillaris,
M. flava, and M. yunnanensis).3 Melissa officinalis
has three main subspecies that have been differentiated (ssp. officinalis,
ssp. altissima, and ssp. inodora4) and at least 15
named cultivars.5 Based on composition of the essential oil, at
least three chemotypes have been identified: citral-, germacrene- and
caryophyllene-types.6
The genus Melissa originated in
the Mediterranean to western and central Asian regions.4 Lemon balm
leaf is wild-collected on a commercial scale in parts of eastern Europe,7,8
southern Europe,9-11 and western Asia.12 The commercial
supply of cultivated lemon balm comes mainly from eastern Europe,4,13,14
southern Europe,4,10,15-17 western Europe,4,18-20
northern Africa,21 North America,4 and South America.4
Most of the certified organic lemon balm
in the global market originates from Albania (wild-collected), Bulgaria
(wild-collected), Egypt (cultivated), Turkey (cultivated), the United Kingdom
(cultivated), and the United States (cultivated).22 There are also
producers of certified fair trade lemon balm in Egypt.21
HISTORY AND CULTURAL SIGNIFICANCE
The genus name Melissa is derived
from the Greek μελισσο (melisso), meaning “bee,” which refers to the
strong attraction that bees have to M. officinalis.4 Swedish
botanist Carl Linnaeus first assigned the genus Melissa in 1737.23
While referred to as “melissa” in the European Pharmacopoeia,24
the preferred standardized common name in the United States is “lemon balm,”
according to the second edition of the American Herbal Products Association’s Herbs
of Commerce.1
One of the earliest known descriptions
of lemon balm appeared in Historia Plantarum by Greek philosopher and
botanist Theophrastus of Eresus (372-287 BCE). Lemon balm remains were detected
in a rodent nest inside a hollow bronze statue of a champion athlete of Greek
origin excavated from the northern Adriatic Sea — probably the cargo of a Roman
ship — that dates back to the Classical period (first century BCE to second
century CE).25 In the 10th century, lemon balm was introduced to
Spain by the occupying Moors and was later brought to central Europe by Benedictine
monks. In her book Physica, written between 1151 and 1158, Benedictine
abbess Hildegard von Bingen (1098-1179) described medicinal uses of lemon balm.26
It is believed that the original idea of “Carmelite Water” (Eau de Carmélite,
also known as “Spirit of Melissa”) may be traced back to around the year 1200,
when Christian hermits, who began living in caves on Mount Carmel after the
Crusaders retook Haifa, first realized the therapeutic properties of lemon
balm.27 Lemon balm is among the 165 medicinal plant species used in
Carinthian monastic medicine of the High Middle Ages (1001-1300), and it is
still cultivated today at Carinthian monasteries in Austria.28
By the 16th century, lemon balm was
being grown in several European countries.26 In his 1543 herbal New
Kreüterbuch, botanist and physician Leonhart Fuchs (1501-1566) wrote that “Melissen”
and “Honigblum” were the traditional names used because of the honey
bee’s special love and desire for the flowers of lemon balm to make honey.29
In France, lemon balm cultivation began
around 1611 in monastery gardens, where a process for distilling lemon balm
water was developed by the Discalced Carmelites* in Paris, and Eau de Carmélite
became a popular remedy for treating toothache, syncope (fainting), and anxiety.
A century later, in 1710, the Discalced Carmelites in Venice began to produce
their version of Acqua di Melissa, but decided to use Dracocephalum
moldavica (syn. M. moldavica) instead of M. officinalis.30
At the end of the 18th century, during a church-hostile phase of the French
Revolution, two Carmelite nuns fled Paris to take refuge at a German monastery
in Baden-Baden and brought with them their secret recipe for Eau de Carmélite.
In this way, the French tradition carried on in Germany where the name of the
elixir changed to Melissengeist. The method of preparing Melissengeist
was known by only the two nuns, who took an oath to pass it on to an initiated
successor only when one of them died. In 2003, the sisters of the Holy
Sepulcher of Baden-Baden came to an agreement with the sisters of Monastère du
Carmel Notre Dame de l’Unité in Develier, Switzerland, to transfer the rights
to manufacture the formula. The transfer took two years and required formal
consent of the Archbishop of Freiburg (the legal owner of the formula) and
authorization from the Swiss Alcohol Board for the manufacture of alcoholic
beverages.31
In 1984, the German Commission E
approved the use of lemon balm leaf, prepared as an herbal infusion, dry
extract or fluidextract, as a nonprescription medicine for treating nervous
sleeping disorders and functional gastrointestinal complaints.32 In
1997, the European Scientific Cooperative on Phytotherapy (ESCOP) indicated
lemon balm internally for tenseness, restlessness, irritability, and for
treatment of minor digestive issues, as well as externally for cold sores
(herpes labialis).33 Since then, national labeling standards
monographs of European Union (EU) member states, such as those of the German
Commission E, have been superseded by monographs of the European Medicines
Agency (EMA).
A quality standards monograph for
“Melissa Leaf” first entered the European Pharmacopoeia (PhEur) in the
2000 supplement to the 1997 third edition,34 and subsequently a
monograph for “Melissa Leaf Dry Extract” was added to the sixth supplement to
the sixth edition (PhEur 6.6) in 2010. Both monographs have remained official
through the current ninth edition published in July 2016.24 In 2004,
a comprehensive monograph (quality and therapeutics) for “Folium Melissae” was
added to volume two of the WHO Monographs on Selected Medicinal Plants,35
and, in 2010, a monograph was included in the WHO Monographs on Medicinal
Plants Commonly Used in the Newly Independent States (NIS).36 In
2007, the EMA published a labeling standards monograph, which was later
superseded by a 2013 revised monograph.37
After the passage of the EU Directive on
Traditional Herbal Medicinal Products (THMPD) of 2004, the first product in
Europe to be issued a product registration under the new framework was
Klosterfrau† Melissengeist (M.C.M.
Klosterfrau Vertriebs GmbH; Cologne, Germany), issued by the German Federal
Institute for Drugs and Medical Devices (BfArM) in December 2005.38
CURRENT AUTHORIZED USES IN COSMETICS, FOODS, AND
MEDICINES
In the United States, the Food and Drug
Administration (FDA) classifies “balm (lemon balm)” as Generally Recognized as
Safe (GRAS) for use as a spice, natural seasoning, or flavoring.39
FDA also classifies essential oils and natural extractives (including distillates)
of lemon balm as GRAS for use in food products.40 Lemon balm is also
permitted as a component of dietary supplement products, which require FDA
notification within 30 days of marketing if a structure-function claim is made
and product manufacturing that conforms with current Good Manufacturing
Practices (cGMPs) for dietary supplements.41
For herbal medicinal product companies
in the EU or in non-EU countries where the PhEur is an official compendium
(e.g., Australia and Canada), the aforementioned PhEur quality monographs can
be used as the basis for active ingredient specifications. Registered
Traditional Herbal Medicinal Products (THMPs) composed of PhEur-quality lemon
balm and prepared as herbal teas, liquid extracts, or as solid dosage forms
containing dry extract, may be labeled and marketed “for relief of mild
symptoms of mental stress and to aid sleep” or “for symptomatic treatment of
mild gastrointestinal complaints including bloating and flatulence.”37
For use in cosmetic products, the European
Commission Health and Consumers Directorate lists “Melissa Officinalis Leaf
Extract” and “Melissa Officinalis Leaf Water” (aqueous solution of the steam
distillates obtained from the leaves) for skin-conditioning function, and
“Melissa Officinalis Leaf Oil” (volatile oil obtained from the leaves and tops)
for masking, perfuming, and tonic functions.42
MODERN
RESEARCH
Chemical constituents found in M.
officinalis include antioxidant phenolic acids, with rosmarinic acid (a
caffeic acid derivative) as the major compound; flavonoids (e.g., luteolin-3’-O-glucuronide)43;
and essential oil (with citronellal, neral, and geranial as the most abundant
constituents)33,44; among others.
In vitro and in vivo studies have shown
lemon balm and its essential oil to have anti-anxiety,45
anti-inflammatory, analgesic,46 antibacterial, antiviral,47-53
antiproliferative, radical scavenging,54,55 sedative,45,56
thyroid-inhibiting,57 hypoglycemic, anti-diabetic
(glucokinase-stimulating),58 antigenotoxic, antimutagenic,59
immunostimulating,60 and anticonvulsive properties.61,62
A number of clinical studies have shown
various positive outcomes when M. officinalis is used in combination
with other herbs. These include the following: promoting sleep (with valerian [Valeriana
officinalis, Caprifoliaceae])63,64; treating restlessness in
children (with valerian)64; stimulating alpha1 electrical brain
activity (with lavender [Lavandula spp., Lamiaceae], hops [Humulus
lupulus, Cannabaceae], and oat [Avena sativa, Poaceae])65;
treating infantile colic (with German chamomile [Matricaria chamomilla,
Asteraceae] and fennel [Foeniculum vulgare, Apiaceae])66;
reducing oxidative stress (with cinnamon [Cinnamomum zeylanicum,
Lauraceae])67 and laboratory-induced stress (with valerian)68;
treating dyspepsia (in STW 5‡ [Steigerwald
Arzneimittelwerk GmbH; Darmstadt, Germany])69; treating abdominal
pain and bloating in patients with irritable bowel syndrome (with spearmint [Mentha
spicata, Lamiaceae] and coriander [Coriandrum sativum, Apiaceae]).70
Unfortunately, despite the approved
uses of lemon balm based on its long history in traditional medicine, there are
few high-quality clinical studies on M. officinalis alone.
A randomized, double-blind,
placebo-controlled (RDBPC) study (N = 58) published in 2016 evaluated the
effect of lemon balm on patients with borderline hyperlipidemia. Outpatients
with total serum cholesterol ranging from 200-260 mg/dL, low-density
lipoprotein (LDL) levels ranging from 100-160 mg/dL, and/or serum triglycerides
ranging from 150-300 mg/dL were randomly assigned to take 1,000 mg encapsulated
lemon balm leaf powder (500 mg per capsule; no further information provided) or
placebo three times per day after meals over two months. Participants were
advised not to change their diet, and their daily intake of carbohydrates,
protein, fiber, and fat were recorded via two 24-hour dietary recall
questionnaires at the beginning and end of the study. No statistical
differences were found within or between groups regarding dietary intake. The
lemon balm group experienced a significant decrease in mg/dL of LDL cholesterol
(139.64 ± 19.06 to 125.68 ± 22.62) compared to the placebo group (129.90 ±
17.94 to 131.07 ± 21.21). While there were no significant differences between
groups in levels of total cholesterol, fasting blood glucose, high-density
lipoprotein (HDL), triglycerides, creatinine, or alanine transaminase (ALT) at
the end of the study, the lemon balm group did not experience the higher
LDL:HDL ratio (a risk factor for atherosclerosis and coronary heart disease)
that was seen in the placebo group. According to the authors, this suggests
that lemon balm may provide protection against atherosclerosis and coronary
heart disease. Additionally, the lemon balm group experienced a significant
change in levels of aspartate transaminase (AST; 23.64 ± 7.36 U/L to 22.30 ±
6.56 U/L) compared to the placebo group (20.27 ± 5.76 U/L to 22.50 ± 6.00 U/L).
Since increased levels of AST are correlated with liver damage, this study
suggests that lemon balm may have the ability to improve liver health, although
the observed decrease is not likely to have a clinically relevant impact.44
Another RDBPC study explored the effect
of lemon balm on heart palpitations, an indication for lemon balm in traditional
Iranian medicine. Participants (N = 55) with “an unpleasant sensation in the
heart or awareness of heartbeat as their main complaint” were randomly assigned
to take 500 mg encapsulated lemon balm dry water extract powder (powdered dry
leaves infused in 1,000 mL boiling water, filtered, then freeze dried; no
additional information provided) or placebo twice daily for 14 days. At the end
of the two-week period, palpitation episodes, based on patients’ diaries, had
decreased by 36.8% in the lemon balm group, compared to a decrease of 4.19% in
the placebo group. Moreover, the lemon balm group had fewer participants with
anxiety and insomnia at the end of the study than the placebo group (decreases
of 42.8% vs. 18.2%, respectively). Change in pain intensity between the two
groups was not significant.71
A 2015 RDBPC study (N = 100)
investigated the effect of lemon balm on the intensity of premenstrual syndrome
(PMS) symptoms in high school girls in Shiraz, Iran, over the course of three
menstrual cycles. Participants with PMS Screening Tool scores greater than 20 (considered
“average symptoms”) were randomly assigned to receive 1,200 mg per day of lemon
balm essence (600 mg capsules made in the pharmacology department of the Shiraz
University of Medical Sciences in Shiraz, Iran) or placebo. The test group
experienced significant reductions in PMS symptom intensity scores from the
onset of the study (42.56 + 15.73) at one month (32.72 ± 13.24), two months
(30.02 ± 12.08), and three months (13.90 ± 10.22). The placebo group experienced non-significant reductions
in intensity of PMS symptoms, which the authors suggest may be attributable to
the placebo effect.72
A randomized, single-blind study (N = 43)
in 2016 compared lemon balm to the nonsteroidal anti-inflammatory drug (NSAID)
mefenamic acid for their ability to relieve dysmenorrhea (i.e., pain associated
with menstruation). From the onset of the menstrual period until the third day
of menstruation, women with moderate-to-severe primary dysmenorrhea were
randomly assigned to drink one cup of lemon balm tea made from tea bags
(Golchai Co.; Alborz, Iran; no additional information provided) or take 250 mg
of mefenamic acid (Razak Laboratories Co.; Tehran, Iran) every eight hours
until pain was relieved. Both groups experienced decreases in pain intensity
and duration over three menstrual cycles, but the lemon balm group experienced
a greater decrease in pain intensity (5.61 ± 1.125 to 3.166 ± 0.632) than the
mefenamic acid group (6.13 ± 1.38 to 4.095 ± 1.70). The authors recognize that
the study’s findings are limited by the small sample size and short follow-up
period.73
Published in 2003, one RDBPC study
investigated the efficacy of lemon balm for treating mild-to-moderate
Alzheimer’s disease (AD) over four months. Patients (N = 42; 65-80 years old)
with scores of 12 or greater on the AD Assessment Scale (ADAS-cog) and 2 or
less on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale were randomly
assigned to receive 60 drops per day of lemon balm extract (1:1 in 45% alcohol,
standardized to contain at least 500 µg citral/mL; no additional information
provided) or placebo. After four months, the lemon balm group experienced a
significant improvement in cognition compared to placebo in both the ADAS-cog
(-6.4 vs. 5.60, respectively) and the CDR-SB scores (-1.92 vs. 1.03, respectively). The authors state
that while lemon balm may be effective in treating mild-to-moderate AD, further
studies with larger sample sizes are needed to confirm lemon balm’s efficacy.
The authors also list the short follow-up period as a limitation, but it is
unclear from the paper if there was a follow-up period at all.74
One RDBPC study published in 2002
evaluated the effectiveness of lemon balm essential oil (LBEO) for managing
agitation in patients with severe dementia. Patients with clinically significant
agitation related to severe dementia (N = 72, mean age = 78.5 ± 8.1 years), who
continued to use prescribed psychotropic medications during the study, were
randomly assigned to receive treatment with LBEO lotion or placebo (sunflower [Helianthus
spp., Asteraceae] oil lotion). The LBEO was obtained from G. Baldwin & Co.
(London, England) and contained 22% citronellal, 18% caryophyllene, 7% neral,
7% geraniol, 3% geranyl acetate, and 4% citronallal. The test preparation was
made by adding 10% by weight LBEO to a base lotion containing almond (Prunus
dulcis, Rosaceae) oil, glycerine, stearic acid, cetearyl alcohol, and
tocopheryl acetate. Over a four-week period, a measured dose of 0.16-0.17 g was
applied for one to two minutes to the patient’s face and arms twice a day for a
total of six doses per day. To achieve blinding, two residential facilities
were used and participants in each facility were given either the active
treatment or placebo.
By the end of the study, the lemon balm
group had experienced a 35% decrease from baseline in agitation on the
Cohen-Mansfield Agitation Inventory (CMAI), compared to an 11% decrease in the
placebo group, a significant between-group difference. Additionally, 21 of 36
subjects (58%) in the active treatment group experienced a clinically
significant improvement in agitation (defined as a 30% improvement) compared to
only five of 36 (14%) in the placebo group. Moreover, the lemon balm group
experienced a significant reduction in the amount of time spent socially withdrawn
and a significant increase in the amount of time participating in constructive
activities. The authors propose several hypotheses for the success of the
treatment: physiological effect(s) of the LBEO terpenes; concentration of the
monoterpene citronellal in the hippocampus after administration; increased
social contact between staff and subjects; the fragrance having a placebo
effect on subjects (considered unlikely as patients with severe dementia
commonly have an impaired sense of smell); and the fragrance having an impact
on the caregivers’ reporting. However, the authors believe that none of these
hypotheses taken individually can explain the magnitude of improvement in the
active treatment group, and they recommend further multicenter studies to confirm
and elucidate their findings.75
FUTURE OUTLOOK
Although classified as a protected
species in Croatia,76 the International Union for Conservation of
Nature (IUCN) European Red List of Medicinal Plants assigns M. officinalis
to the conservation category of least concern, meaning that the species is not
threatened in Europe.77 However, the situation is different in parts
of Asia. In Iran, wild M. officinalis is reportedly threatened due to
habitat destruction, land use changes, and overharvesting.78 In
Armenia, field studies on changes in distribution and structure of wild M.
officinalis populations were carried out from 2006 to 2009.79 A
related eco-geographic survey of population dynamics of wild M. officinalis
was conducted from 2007 to 2011.80 While historical data had shown
that wild M. officinalis populations were widely distributed in northern
and central regions of Armenia, nearly half of the populations no longer
existed in the previously cited locations. There is also evidence that the
distribution of M. officinalis is expanding in southern Armenia. Current
models predict that vulnerability of wild populations in central and northern
Armenia will increase due to anthropogenic threats (e.g., poor land management,
deforestation, livestock overpopulation, and unsustainable wild-collection
methods) and climate change (e.g., more frequent early spring frosts and abrupt
weather changes).81
One of the biggest markets for lemon balm
is Germany, where the average annual demand is about 1.5 million kg (3.307
million lbs). While Germany imports most of its lemon balm supply, about 20% is
grown in Germany on about 120 hectares (296.5 acres).82 There are
approximately 38 hectares (94 acres) of lemon balm cultivation in neighboring
France.19 Bulgaria remains one of the main producers and exporters
of both wild-collected and cultivated lemon balm with an annual average export
volume of 330,629 kg (728,912 lbs) Folium Melissae (leaf), plus another 118,840
kg (261,997 lbs) of Herba Melissae (aerial parts), and 11,400 kg (25,132 lbs)
of Herba Melissae Stipites (stem).83 In 2015, Bulgaria had about 410
hectares (1,013 acres) of lemon balm cultivation with an overall yield of
550,000 kg (1.212 million lbs).84 Albania exports about 350,000 kg
(771,618 lbs) of wild-collected lemon balm annually.10 Hungary has
an estimated 200-250 hectares (494-618 acres) of lemon balm cultivation with an
annual production of up to 300,000 kg (661,387 lbs).85 In the United
States, there are many small- to medium-sized organic lemon balm growers in
several states, including California, Oregon, Washington, Vermont, Maine, and
New York.22
There are no indications that the demand
for lemon balm for use in herbal medicinal products, herbal dietary
supplements, foods, and beverages will decrease. Although lemon balm is now
cultivated in many countries worldwide, the main production areas and highest
demand remain in Europe, especially Germany. There is evidence that both
cultivated and wild-collected lemon balm
are increasingly being produced according to international sustainability
standards, such as organic and fair trade. The production and market scenario
appear stable.
—Gayle Engels and Josef Brinckmann
* The Order of the Discalced
Carmelites, founded in 1562, is a mendicant monastic order (i.e., dependent on
charity) of the Roman Catholic Church. “Discalced” comes from the Latin word for
“barefoot.”
†
Klosterfrau, literally translated as “cloister woman,” is a German term for
“nun.”
‡ STW 5 is
a combination herbal product that also contains bitter candytuft (Iberis
amara, Brassicaceae), angelica (Angelica archangelica, Apiaceae),
milk thistle (Silybum marianum, Asteraceae), caraway (Carum carvi,
Apiaceae), celandine (Chelidonium majus, Papaveraceae), licorice (Glycyrrhiza
glabra, Fabaceae), German chamomile, and peppermint (Mentha × piperita,
Lamiaceae).
References
- McGuffin M, Kartesz JT, Leung AY, Tucker
AO. American Herbal Products Association’s Herbs of Commerce. 2nd ed.
Silver Springs, MD: American Herbal Products Association; 2000.
- Applequist W. The Identification of
Medicinal Plants: A Handbook of the Morphology of Botanicals in Commerce.
St. Louis, MO: Missouri Botanical Garden; 2006.
- The Plant List (2013). Version 1.1.
2013. Available at: www.theplantlist.org/tpl1.1/search?q=Melissa.
Accessed April 15, 2017.
- Bomme U, Honermeier B, Hoppe B, Kittler
J, Lohwasser U, Marthe F. Melisse (Melissa officinalis L.). In: Hoppe B,
ed. Handbuch des
Arznei- und Gewürzpflanzenbaus, Band 5. Bernburg: Verein für Arznei- und
Gewürzpflanzen SALUPLANTA e.V. Bernburg; 2013:151-173.
- Heine H, Eger H,
Franz C, Blüthner W-D, Hoppe K. Sortenwesen und Sortenübersicht Arznei- und
Gewürzpflanzen. In: Verein für Arznei- und Gewürzpflanzen SALUPLANTA e.V.
Bernburg, ed. Handbuch des Arznei- und Gewürzpflanzenbaus, Band I.
Bernburg: Verein für Arznei- und Gewürzpflanzen SALUPLANTA e.V. Bernburg; 2009.
- Kittler J, Krüger
H, Schütze W, et al. Charakterisierung unterschiedlicher Genpools der Melisse (Melissa
officinalis) als Basis für die Entwicklung von züchterisch wertvollem
Ausgangsmaterial. In: Humboldt-Universität zu Berlin, ed. 6. Fachtagung
Arznei- und Gewürzpflanzen. Berlin: Deutscher Fachausschuß für Arznei-,
Gewürz- und Aromapflanzen; 2011.
- Bakalski Co. Ltd. List of Wild Collected Organic Herbs, season 2010.
Available at: www.bakalskico.com/products/organic-wild-collected-herbs.html
Accessed April 15, 2017.
- Viola Ltd. List of Wild Collected
Organic Herbs. Available at: www.viola.bg/LISTOFWILDCOLLECTED2009.pdf.
Accessed April 16, 2017.
- AgroHerbAl sh.p.k. Products. Available
at: www.agroherbal.net/products-natural-biologic-organic-agroherbal.html.
Accessed April 16, 2017.
- Kathe W, Honnef S, Heym A. Medicinal
and Aromatic Plants in Albania, Bosnia-Herzegovina, Bulgaria, Croatia and
Romania. Bonn, Germany:
Bundesamt für Naturschutz (BfN);2003.
- Brinckmann JA,
Huggins K, Gardner ZE. Managing Natural Resources for
Sustainable Livelihoods: Threats to the Future of Sustainable Wild Collection
and Field Experience with Implementation of the FairWild Standard for Medicinal
Plants. International Journal on Biodiversity Watch. 2014;3:13-29.
- ANTARAM PC. Medicinal herbs and herbal
teas. Yerevan, Armenia: ANTARAM PC; 2017.
- Bernáth J, Németh E. Main fields of
research activity on medicinal and aromatic plant species in Hungary in
relation to the ECPGR “priority list”. In: Lipman E, ed. Report of a Working
Group on Medicinal and Aromatic Plants. Second Meeting, 16‑18
December 2004, Strumica, Macedonia FYR / Third Meeting, 26–28 June 2007,
Olomouc, Czech Republic. Rome, Italy:
Bioversity International; 2009:115-128.
- Węglarz Z, Geszprych A. The status of
medicinal and aromatic plants in Poland. In: Baričevič D, Bernáth J, Maggioni
L, Lipman E, eds. Report of a Working Group on Medicinal and Aromatic
Plants. First meeting, 12-14 September 2002, Gozd Martuljek, Slovenia.
Rome, Italy: International Plant Genetic Resources Institute; 2004:96-105.
- Foreign Trade Chamber of Bosnia and
Herzegovina. Catalogue: Medicinal & Aromatic Plants | Mushrooms | Forest
Fruits | Honey. Sarajevo: USAID/Sida FARMA; 2014.
- Albinspekt. Organic Certificate: Annex C
- Processed products - Agroproduct shpk - List of certified products. 2017.
Available at: http://albinspekt.com/site.OLD/wp-content/uploads/2017/01/Annex-C_List-of-products-AP-170124.pdf.
Accessed April 18, 2017.
- Zivanovic ST, Stevanetic S, Ceranic S,
Zivanovic T. Trends in production of raw medicinal and aromatic plants in
Serbia. Paper presented at: Fifth International Scientific Agricultural
Symposium “Agrosym 2014” - Jahorina, Bosnia and Herzegovina, October 23-26,
2014.
- Kainz W. Medicinal and aromatic plants
in Austria – status 2007. In: Lipman E, ed. Report of a Working Group on
Medicinal and Aromatic Plants. Second Meeting, 16‑18
December 2004, Strumica, Macedonia FYR / Third Meeting, 26–28 June 2007,
Olomouc, Czech Republic. Rome, Italy:
Bioversity International; 2009:45-58.
- Délégation nationale de FranceAgriMer
Volx. Données et bilans: Filières plantes à parfum, aromatiques et médicinales
Panorama 2015 / direction Marchés, études et prospective. Montreuil cedex:
FranceAgriMer; 2016.
- Organic Herb Trading Company. Online
Price List. Available at: www.organicherbtrading.com/.
Accessed April 18, 2017.
- FLO-CERT GmbH Fairtrade customer search.
Available at: www.flocert.net/fairtrade-services/fairtrade-certification/fairtrade-customer-search/.
Accessed April 16, 2017.
- Organic INTEGRITY Database. USDA,
Agricultural Marketing Service; 2017. Available at: https://organic.ams.usda.gov/Integrity/.
Accessed April 16, 2017.
- Linnæi C. Genera plantarum :eorumque
characteres naturales secundum numerum, figuram, situm, & proportionem
omnium fructificationis partium. Batavorum Lugdunum [Leiden]: Conradum
Wishoff; 1737.
- European Pharmacopoeia Commission. European
Pharmacopoeia Ninth Edition (PhEur 9.0). Strasbourg, France: European
Directorate for the Quality of Medicines; 2016.
- Šoštarić R, Kovačić D, Ćaleta M, Alegro
A, Mitić B. The Croatian Apoxyomenos as a luxurious rodent nest: archaeobotanical
and zoological analyses of organic material found inside the classical bronze
statue. Vegetation History and Archaeobotany. 2007;17(3):289-295.
- Teuscher E. Medicinal Spices: A
Handbook of Culinary Herbs, Spices, Spice MIxtures and their Essential Oils.
Stuttgart: Medpharm
Scientific Publishers; 2006.
- Heckelmann H. Maria
Clementine Martin (1775-1843) Ordensfrau, “Quacksalberin,” Unternehmerin. Eine rechtshistorische Untersuchung aus
neuen Quellen, Universität
Regensburg; 2014.
- Kartnig T, Piendl
S. Arzneipflanzen und Arzneidrogen in der Klostermedizin in Kärnten einst und
jetzt. Carinthia II, Klagenfurt. 2004;194(114):83–95.
- Fuchs L. New
Kreüterbuch / in welchem nit allein die gantz histori / das ist / namen /
gestalt/ statt und Zeit der wachsung / natur / krafft un würkung / des meysten
theyls der Kreuter so in Teutschen unnd andern Landen wachsen / mit dem besten
vleiß beschrieben. Basel, Switzerland: Michael Isingrin;
1543.
- Favero C, Favero G. The Discalced
Carmelites in Venice - The Church of Santa Maria di Nazareth and the Monastery
Garden. BIBLOS EDIZIONI,
Cittadella (Pd), Italy; 2015.
- Gönnheimer S.
Schätze aus der Schulstiftung der Erzdiözese – Das Elexier der Karmeliterinnen.
FORUM Schulstiftung. 2006;45:106-109.
- Blumenthal M, Busse
WR, Goldberg A, Gruenwald J, Hall T, Riggins CW, Rister RS, eds. Klein S, Rister RS, trans. The Complete German
Commission E Monographs — Therapeutic Guide to Herbal Medicines. Austin,
TX: American Botanical Council; Boston: Integrative Medicine Communication;
1998.
- ESCOP. Melissae folium. Monographs on
the Medicinal Uses of Plant Drugs. Exeter, UK: European Scientific
Cooperative on Phytotherapy; 1997.
- European Pharmacopoeia Commission. Europäisches Arzneibuch Nachtrag 2000. Stuttgart/Eschborn: Deutscher
Apotheker Verlag/Govi-Verlag - Pharmazeutischer Verlag GmbH; 2000.
- World Health Organization. WHO
Monographs on Selected Medicinal Plants, Volume 2. Geneva: World Health
Organization; 2002.
- World Health Organization. WHO
Monographs on Medicinal Plants Commonly Used in the Newly Independent States
(NIS). Geneva, Switzerland: World Health Organization; 2010.
- Committee on Herbal Medicinal Products
(HMPC). Community herbal monograph on Melissa officinalis L., folium. London, UK: European Medicines
Agency; 2013.
- Deutsches Institut
für Medizinische Dokumentation und Information (DIMDI). Gebrauchsinformation:
Klosterfrau Melissengeist. In: PharmNet.Bund. Arzneimittel-Informationssystem.
2005; Available at: www.pharmnet-bund.de/dynamic/de/arzneimittel-informationssystem/index.html.
Accessed April 16, 2017.
- US Food and Drug
Administration (FDA). § 182.10 Spices and other natural seasonings and flavorings. Code of Federal Regulations, Title 21 (21 CFR). Washington, DC: US Government Printing Office;
2016:474-475.
- US Food and Drug Administration. §
182.20 Essential oils, oleoresins (solvent-free), and natural extractives
(including distillates). In: Code of Federal Regulations (21 CFR). Washington,
DC: US Government Printing Office; 2016.
- US Food and Drug Administration. 21 CFR
Part 111 Current Good Manufacturing Practice in Manufacturing, Packaging,
Labeling, or Holding Operations for Dietary Supplements; Final Rule. Federal
Register. 2007;72(121):34752-34958.
- Cosmetic Ingredients and Substances
(CosIng®) Database. European Commission; 2017. Available at: http://ec.europa.eu/growth/tools-databases/cosing/.
Accessed April 16, 2017.
- Herodež
ŠS Hadolin M, Škerget
M, Knez Ž. Solvent
extraction study of antioxidants from balm (Melissa officinalis L.)
leaves. Food Chem. 2003;80:275-282.
- Jandaghi P, Noroozi M, Ardalani H,
Alipour M. Lemon balm: A promising herbal therapy for patients with borderline
hyperlipidemia–A randomized double-blind placebo-controlled clinical trial. Complement
Ther Med. 2016;26:136-140.
- Heinrich M, Barnes J, Gibbons S,
Williamson EM. Fundamentals of Pharmacognosy and Phytotherapy. London,
UK: Elsevier; 2012.
- Birdane YO Büyükokuroglu M, Birdane FM, Cemek M, Yavuz H. Anti-inflammatory and
antinociceptive effects of Melissa officinalis L. in rodents. Revue
Med Vet. 2007;158(2):75-81.
- Pourghanbari G, Nili H, Moattari A,
Mohammadi A, Iraji A. Antiviral activity of the oseltamivir and Melissa
officinalis L. essential oil against avian influenza A virus (H9N2). Virusdisease.
2016;27(2):170-178.
- Astani A, Navid MH, Schnitzler P.
Attachment and penetration of acyclovir-resistant herpes simplex virus are
inhibited by Melissa officinalis extract. Phytother Res. 2014;28(10):1547-1552.
- Astani A, Reichling J, Schnitzler P. Melissa
officinalis extract inhibits attachment of herpes simplex virus in vitro. Chemotherapy.
2012;58(1):70-77.
- Schnitzler P, Schuhmacher A, Astani A,
Reichling J. Melissa officinalis oil affects infectivity of enveloped
herpesviruses. Phytomedicine. 2008;15(9):734-740.
- Mazzanti G, Battinelli L, Pompeo C, et
al. Inhibitory activity of Melissa officinalis L. extract on Herpes
simplex virus type 2 replication. Nat Prod Res. 2008;22(16):1433-1440.
- Nolkemper S, Reichling J, Stintzing FC,
Carle R, Schnitzler P. Antiviral effect of aqueous extracts from species of the
Lamiaceae family against Herpes simplex virus type 1 and type 2 in vitro. Planta
Med. 2006;72(15):1378-1382.
- Allahverdiyev A, Duran N, Ozguven M,
Koltas S. Antiviral activity of the volatile oils of Melissa officinalis
L. against Herpes simplex virus type-2. Phytomedicine. 2004;11(7-8):657-661.
- Čanadanović-Brunet
J, Ćetković G, Djilas S,
et al. Radical scavenging, antibacterial, and antiproliferative activities of Melissa
officinalis L. extracts. Journal of Medicinal Food. 2008;11(1):133-143.
- Jeziorek M, Wasek M. Free radical
scavenging activity for infusions of 30 medicinal plants detected with electron
paramagnetic resonance. Herba Polonica. 2008;54(1):7-14.
- Soulimani R, Fleurentin J, Mortier F,
Misslin R, Derrieu G, Pelt JM. Neurotropic action of the hydroalcoholic extract
of Melissa officinalis in the mouse. Planta Med. 1991;57(2):105-109.
- Santini F, Vitti P, Ceccarini G, et al.
In vitro assay of thyroid disruptors affecting TSH-stimulated adenylate cyclase
activity. J Endocrinol Invest. 2003;26(10):950-955.
- Chung MJ, Cho SY, Bhuiyan MJ, Kim KH,
Lee SJ. Anti-diabetic effects of lemon balm (Melissa officinalis) essential
oil on glucose- and lipid-regulating enzymes in type 2 diabetic mice. Br J
Nutr. 2010;104(2):180-188.
- Cassettari de Carvalho N,
Corrêa-Angeloni MJF, Leffa DD, Moreira J, et al. Evaluation of the genotoxic
and antigenotoxic potential of Melissa officinalis in mice. Genetics
and Molecular Biology. 2011;34(2):290-297.
- Drozd J, Anuszewska E. The effect of
the Melissa officinalis extract on immune response in mice. Acta Pol
Pharm. 2003;60(6):467-470.
- Hariry RE. Anticonvulsant effects of
hydroalcoholic extract of Melissa officinalis on pentylenetetrazole
(PTZ) model of convulsion in mice. J Med Plant Research. 2011;5(16):3803-3809.
- Gorgich E, Komeili G, Zakeri Z,
Ebrahimi S. Comparing anticonvulsive effect of Melissa officinalis hydro-alcohlic
extract and phenytoin in rat. Journal of Health Scope. 2012;1(1):44-48.
- Dressing H, Köhler S, Müller WE.
Improvement of sleep quality with a high-dose valerian/lemon balm preparation:
a placebo-controlled double-blind study. Psychopharmakotherapie. 1996;3:123-130.
- Müller
SF, Klement S. A combination of valerian and lemon balm is effective in the
treatment of restlessness and dyssomnia in children. Phytomedicine. 2006;13(6):383-387.
- Dimpfel W, Pischel I, Lehnfeld R.
Effects of lozenge containing lavender oil, extracts from hops, lemon balm and
oat on electrical brain activity of volunteers. Eur J Med Res. 2004;9(9):423-431.
- Savino F, Cresi F, Castagno E,
Silvestro L, Oggero R. A randomized double-blind placebo-controlled trial of a
standardized extract of Matricariae recutita, Foeniculum vulgare
and Melissa officinalis (ColiMil) in the treatment of breastfed colicky
infants. Phytother Res. 2005;19(4):335-340.
- Rashidi M, Malekirad AA, Abdollahi M,
Habibollahi S, Dolatyari N, Narimani M. The effect of tea-cinnamon and Melissa
officinalis L. aqueous extraction, on neuropsychology distress, biochemical
and oxidative stress biomarkers in glass production workers. Health. 2014;6:2592-2601.
- Kennedy DO, Little W, Haskell CF,
Scholey AB. Anxiolytic effects of a combination of Melissa officinalis
and Valeriana officinalis during laboratory induced stress. Phytother
Res. 2006;20(2):96-102.
- Rösch
W, Liebregts T, Gundermann KJ, Vinson B, Holtmann G. Phytotherapy for
functional dyspepsia: a review of the clinical evidence for the herbal
preparation STW 5. Phytomedicine. 2006;13 Suppl 5:114-121.
- Vejdani R, Shalmani HR, Mir-Fattahi M,
et al. The efficacy of an herbal medicine, Carmint, on the relief of abdominal
pain and bloating in patients with irritable bowel syndrome: a pilot study. Dig
Dis Sci. 2006;51(8):1501-1507.
- Alijaniha F, Naseri M, Afsharypuor S,
et al. Heart palpitation relief with Melissa officinalis leaf extract:
double blind, randomized, placebo controlled trial of efficacy and safety. Journal
of Ethnopharmacology. 2015;164:378-384.
- Akbarzadeh M, Dehghani M, Moshfeghy Z,
Emamghoreishi M, Tavakoli P, Zare N. Effect of Melissa officinalis
capsule on the intensity of premenstrual syndrome symptoms in high school girl
students. Nurs Midwifery Stud. 2015;4(2):e27001.
- Faranak SD, Parvin N. The effect of
mefenamic acid and Melissa officinalis on primary dysmenorrhea: a
randomized clinical trial study. International Journal of Pharmacognosy and
Phytochemical Research. 2016;8(8):1286-1292.
- Akhondzadeh S, Noroozian M, Mohammadi M,
Ohadinia S, Jamshidi AH, Khani M. Melissa officinalis extract in the
treatment of patients with mild to moderate Alzheimer’s disease: a double
blind, randomised, placebo controlled trial. J Neurol Neurosurg Psychiatry. 2003;74(7):863-866.
- Ballard CG, O’Brien JT, Reichelt K,
Perry EK. Aromatherapy as a safe and effective treatment for the management of
agitation in severe dementia: the results of a double-blind, placebo-controlled
trial with Melissa. J Clin Psychiatry. 2002;63(7):553-558.
- Sandev D, Mihelj D, Kovačić S. Meeting
Target Eight – Ex situ conservation of Croatian threatened and statutorily
protected plant species in the Botanical Garden of the Faculty of Science,
University of Zagreb (Croatia). Natura Croatica. 2013;22(2):343–362.
- Allen D, Bilz M, Leaman DJ, Miller RM,
Timoshyna A, Window J. European Red List of Medicinal Plants. Luxembourg: Publications
Office of the European Union; 2014.
- Ghaffariyan S, Mohammadi SA, Aharizad S.
DNA isolation protocol for the medicinal plant lemon balm (Melissa
officinalis, Lamiaceae). Genet Mol Res. 2012;11(2):1049-1057.
- Abrahamyan A. Changes in distribution
and structure of wild Melissa officinalis L. populations during the last
decade in Armenia and implications for conservation. Environment.
Technology. Resources. Proceedings of the 8th International Scientific and
Practical Conference. 2011;2:321-324.
- Abrahamyan A, Barsevskis A, Melikyan A.
Populations dynamics in sizes of wild Melissa officinalis L. (Lamiaceae)
during the last decade in Armenia. Journal of Medicinal Plants Studies. 2015;3(1):21-26.
- Abrahamyan A, Teilans A, Zorins A.
Climate change impact on conservation status of wild Melissa officinalis
L. (Lamiaceae) populations in Armenia. Paper presented at: First International
Symposium on Medicinal, Aromatic and Nutraceutical Plants from Mountainous
Areas (MAP-Mountain 2011), 6th – 9th July 2011, Saas-Fee, Switzerland.
- Kästner U, Krüger
H, Krähmer A, et al. Züchterische Bearbeitung von Melisse (Melissa
officinalis). Paper presented at: 26. Bernburger
Winterseminar Arznei- und Gewürzpflanzen - February 23-24, 2016; Bernburg.
- Evstatieva L, Hardalova R, Stoyanova R.
Medicinal plants in Bulgaria: diversity, legislation, conservation and trade. Phytologia
Balcanica. 2007;13(3):415-427.
- Boshnakova M. GAIN Report Number:
BU1653. Bulgaria Organic Sector and Trade Update. Sofia: USDA Foreign
Agricultural Service; 2016.
- Non-food Group Department of
Agricultural Chemical Technology Budapest University of Technology and
Economics. Report from the Republic of Hungary. Budapest, Hungary:
Interactive European Network for Industrial Crops and their Applications; 2002
(with updates in January 2004).
|
|
|
|
|
|
|